Aberdeen and London, UK – 30 October 2013 – NovaBiotics Ltd, the clinical-stage biotechnology company, today announced that it has partnered with the Cystic Fibrosis Trust and Health Sciences Scotland, for a Phase1/2a clinical trial of its novel compound, Lynovex®.
Lynovex is being developed as a treatment for persistent lung infection in cystic fibrosis (CF). The product works by breaking down excessive mucus and killing the bacteria responsible for recurring infections. It also prevents pathogens establishing long-term, antibiotic resistant infections which are common to people living with CF.
Although in its early stages of development, Lynovex is a drug already approved for oral delivery in an unrelated orphan metabolic disease and has been shown to be safe and well tolerated so has the potential for fast-track clinical development. It has designated orphan drug status in Europe.
Cystic Fibrosis Trust’s support, NovaBiotics is also working in partnership with NHS Grampian and the University of Aberdeen’s CF research team who will undertake initial clinical evaluation and trials of Lynovex.
Deborah O’Neill, CEO of Novabiotics said: “CF is a life-shortening respiratory disease where the treatments available require a complete re-think. Current options for patients are limited and focus primarily on either the recurrent infections or the over-production of mucus. We believe, with Lynovex, we have a much-needed solution for patients that tackles both of these issues.
“Having the Cystic Fibrosis Trust supporting us is a real boost to our clinical efforts and we are grateful to the Aberdeen CF Patient Group for creating this alliance. With Lynovex, we hope to realise our ambition to improve patients’ lives with an effective, safe, long-term therapy.”
Ed Owen, Chief Executive of the Cystic Fibrosis Trust added: “Working collaboratively with academics and industry increases our capacity to support transformational research projects to help develop new drugs for people living with cystic fibrosis. We are pleased to be part funding this project and look forward to the results.
“This work forms part of our five year strategy which aims to see the trust engage closely with partners in research and industry, to develop new therapies and treatment, such as Lynovex, to further the quality and length of life of all people with cystic fibrosis.”
Trials will begin in the New Year with results expected at the end of 2014.
Notes to Editors
NovaBiotics is developing novel peptide antifungal and antibacterial therapeutics that have the ability to treat a range of poorly served and clinically challenging infections. The mechanism of action of NovaBiotics’ drug candidates minimises or negates the chance of drug resistance developing in the target microbes/infections which they have been designed to treat. NovaBiotics’ antifungal and antibacterials are not toxic to human cells at therapeutic doses unlike many conventional antimicrobial medications. NovaBiotics’ lead clinical programme is Novexatin®. In addition to Novexatin®, the Company is developing Lynovex®, for cystic fibrosis (CF) an antibacterial compound that also breaks down excess mucous produced in the airways of CF patients that is expected to enter a Phase IIa study in Q1 2014; Novamycin®, a peptide antifungal agent against Candida and Aspergillus; Novarifyn®, a peptide antibacterial for difficult to treat multi-drug resistant Gram-negative and Gram-positive infections, including MRSA. Further information is available at www.novabiotics.co.uk.
About the Cystic Fibrosis Trust
• Cystic fibrosis is chronically misunderstood, kills thousands worldwide and is carried unknowingly in the genes of millions. It's often invisible to the naked eye yet destroys lives, stopping them short, inflicting hardship and distress on patients, their families and carers. Cystic fibrosis directly affects around 10,000 people in the UK.
• Fighting it is a battle we must win. That’s why we must keep working for and fundraising for change. That's why we must develop better treatments and, ultimately, a cure.
• The faulty gene is carried by over two million people in the UK, most of whom have no idea. If two carriers have children, there’s a one in four chance their child will have the condition, which slowly destroys the lungs and digestive system.
• We’re here to beat it and make a daily difference to the lives of those with cystic fibrosis, and the people who care for them.
Find out more at: www.cysticfibrosis.org.uk or call our helpline 0300 373 1000.
About Cystic Fibrosis
Cystic fibrosis is a life-shortening inherited disease, affecting over 10,000 people in the UK and 70,000 Worldwide. Ninety percent of patients are diagnosed before the age of 17 and it is the number one genetic killer of children and young adults. Finding a treatment that can tackle the common infections and resistance that affect and shorten lives is a priority for patients and their families.
Issued for and on behalf of Novabiotics.
To contact a member of the Novabiotics team, email email@example.com
Melanie Toyne-SewellManaging Partner